Search Results | Blood | American Society of Hematology

1-20 of 1881

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL

Blood (2021) 137 (18): 2463–2480.

DOI: https://doi.org/10.1182/blood.2019004547

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

DOI: https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

DOI: https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Thura Win Htut, MBBS, MRCP, Kyaw Zin Thein, MDMBBS, Anita Sultan, MD, Sriman Swarup, MDMBBS, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Sanjay Awasthi, MD, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD

Blood (2019) 134 (Supplement_1): 3485.

DOI: https://doi.org/10.1182/blood-2019-123145

Published: 2019

Journal Articles

I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 4752.

DOI: https://doi.org/10.1182/blood-2019-122285

Published: 2019

Journal Articles

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Haitham Abdelhakim, MD, Luis M. Cortez, BS, Meizhang Li, PhD, Mitchell Braun, BS, Barry S. Skikne, MD, Tara L. Lin, MD, Neil Dunavin, MD, Andrew K Godwin, PhD

Blood (2019) 134 (Supplement_1): 3605.

DOI: https://doi.org/10.1182/blood-2019-129455

Published: 2019

Journal Articles

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Karthik Gnanapandithan, MD MS, Prakash Kharel, MD, Alyssa Grimshaw, MSLIS, Smith Giri, MBBS

Blood (2019) 134 (Supplement_1): 3606.

DOI: https://doi.org/10.1182/blood-2019-132203

Published: 2019

Journal Articles

Small Molecule Screening Identifies Rho-Associate Protein Kinase (ROCK) As a Regulator of NK Cell Cytotoxicity Against Cancer

Grace Lee, Sheela Karunanithi, Zachary Jackson, David Wald, MD PhD

Blood (2019) 134 (Supplement_1): 3607.

DOI: https://doi.org/10.1182/blood-2019-131947

Published: 2019

Journal Articles

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Jorge Monge, MD, Jorge Contreras, MD, Sarah Elsoukkary, MD, Jin Guo, MD, Art Perry, PA, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Morton Coleman, MD, Adriana C. Rossi, MDMSc, Rebecca Harris, MD, Markus Plate, MD, Joerg-Patrick Stuebgen, MB, ChB, MD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 4876.

DOI: https://doi.org/10.1182/blood-2019-122134

Published: 2019

Journal Articles

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Varun Mehra, MBBS,MRCP,FRCPath, Daniele Avenoso, MD, Ximena Cabrera Castellano, Adrian Choy, Stefani Widya, Mili Shah, FRCPath, Shafqat Inam, MD, Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath,MPhil, Austin Kulasekararaj, MD MRCP, FRCPath, Francesco Dazzi, PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Hugues De Lavallade, Victoria Potter, MBBS, BSc, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4622.

DOI: https://doi.org/10.1182/blood-2019-131239

Published: 2019

Journal Articles

Older Patients with NPM1 Mutated AML Have Distinctive Genomic Mutation Landscape Associated with Enrichment in Immunosuppressive Gene Signature

Haitham Abdelhakim, MD, Ahmad Elkhanany, MD, Mohammad Telfah, MD, Tara L. Lin, MD, Andrew K Godwin, PhD

Blood (2019) 134 (Supplement_1): 1402.

DOI: https://doi.org/10.1182/blood-2019-131296

Published: 2019

Journal Articles

Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia

Hassan Awada, Teodora Kuzmanovic, Ashwin Kishtagari, MBBS, Jibran Durrani, Arda Durmaz, Sanghee Hong, MD, Cassandra M Kerr, MS, Vera Adema, PhD, Yihong Guan, PhD, Sonia Sandhu, Aziz Nazha, MD, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1405.

DOI: https://doi.org/10.1182/blood-2019-131953

Published: 2019

Journal Articles

CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model

Myrna Nahas, MD, Dina Stroopinsky, PhD, Marzia Capelletti, PhD MBBS, Jacalyn Rosenblatt, MD, Shira Orr, PhD, Haider Ghiasuddin, Adam Morin, Jessica Liegel, MD, Donald Kufe, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 1386.

DOI: https://doi.org/10.1182/blood-2019-122438

Published: 2019

Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Blood (2019) 134 (Supplement_1): 1540.

DOI: https://doi.org/10.1182/blood-2019-131367

Published: 2019

Journal Articles

Gastrointestinal Plasmoblastic Lymphoma Associated with Wiskott-Aldrich Syndrome: A Case Report

Ali Unal, MD, Serhat Çelik, Zeynep Güven, MD, Leylagul Kaynar, MD, Bulent Eser, MD, Mustafa Çetin

Blood (2019) 134 (Supplement_1): 5359.

DOI: https://doi.org/10.1182/blood-2019-123387

Published: 2019

Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 5238.

DOI: https://doi.org/10.1182/blood-2019-131941

Published: 2019

Journal Articles

The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets

Edward Truelove, MBBS, BSc, MRCP, FRCPath, Frances Seymour, MRCP, BSc, MBBS, Joseph G Taylor, MBBS, BSc, Mariarita Calaminici, Andrew James Clear, BSc, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 5240.

DOI: https://doi.org/10.1182/blood-2019-130712

Published: 2019

Journal Articles

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Julio C. Chavez, MD, Ariel F Grajales-Cruz, MD, Virginia Olivia Volpe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Eva Sahakian, PhD, Nicole Rozario, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5483.

DOI: https://doi.org/10.1182/blood-2019-132211

Published: 2019

Journal Articles

Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia

Francesca Arruga, PhD, Giulia Guerra, Denis Baev, PhD, Catherine Hoofd, PhD, Marta Coscia, MD PhD, Giovanni Francesco D'Arena, MD, Gianluca Gaidano, MD PhD, Richard R. Furman, MD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 5454.

DOI: https://doi.org/10.1182/blood-2019-128308

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

DOI: https://doi.org/10.1182/blood-2019-124406

Published: 2019

2 3 4 5

NARROW

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL

How I treat warm autoimmune hemolytic anemia

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series

Small Molecule Screening Identifies Rho-Associate Protein Kinase (ROCK) As a Regulator of NK Cell Cytotoxicity Against Cancer

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience

Older Patients with NPM1 Mutated AML Have Distinctive Genomic Mutation Landscape Associated with Enrichment in Immunosuppressive Gene Signature

Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia

CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Gastrointestinal Plasmoblastic Lymphoma Associated with Wiskott-Aldrich Syndrome: A Case Report

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only